Holen Sie sich die Stockscreener-App
0.7975
0.59%
0.0047
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - GlobeNewswire
Clearside Biomedical Announces Multiple Presentations to be Feat - GuruFocus
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting | CLSD Stock News - GuruFocus
Clearside Biomedical Showcases Suprachoroidal Injection Platform for Retinal Diseases at CTS Meeting - Nasdaq
Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Northern Trust Corp Has $157,000 Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical Approves Share Increase at Annual Meeting - TipRanks
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know - MSN
Clearside Biomedical (CLSD) Gets a Buy from H.C. Wainwright - The Globe and Mail
Clearside Biomedical’s SWOT analysis: eye disease stock faces funding hurdles amid promising pipeline - Investing.com India
Clearside Biomedical target cut to $5 by H.C. Wainwright - Investing.com
HC Wainwright Lowers Clearside Biomedical (NASDAQ:CLSD) Price Target to $5.00 - Defense World
Clearside Biomedical (CLSD) Price Target Lowered by Analyst | CL - GuruFocus
H.C. Wainwright Adjusts Price Target for Clearside Biomedical (C - GuruFocus
Clearside Biomedical (CLSD) Price Target Lowered by Analyst | CLSD Stock News - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the St - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum | CLSD Stock News - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - GlobeNewswire
Clearside Biomedical Reveals Next-Gen Eye Therapy Platform at Exclusive Stifel Conference - Stock Titan
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.00 - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.com - Defense World
Needham & Company LLC Lowers Clearside Biomedical (NASDAQ:CLSD) Price Target to $3.00 - Defense World
JMP maintains $5 target on Clearside Biomedical stock By Investing.com - Investing.com Nigeria
Clearside Biomedical (CLSD) Reiterates Market Outperform Rating - GuruFocus
Clearside Biomedical Reports Q1 2025 Financial Progress - TipRanks
Clearside Biomedical (CLSD) Target Price Lowered by Needham | CL - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates - MSN
Stifel maintains Buy on Clearside Biomedical, target at $8 By Investing.com - Investing.com South Africa
Stifel maintains Buy on Clearside Biomedical, target at $8 - Investing.com Australia
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings: EPS Matches Es - GuruFocus
Clearside (CLSD) Reports Strong Q1 Revenue Boost | CLSD Stock Ne - GuruFocus
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings: EPS Matches Estimates at -$0.11, Revenue Surges to $2.3 Million, Exceeding Expectations - GuruFocus
Clearside Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside (CLSD) Reports Strong Q1 Revenue Boost | CLSD Stock News - GuruFocus
Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Clearside Biomedical (NASDAQ:CLSD) Cut to “Sell” at StockNews.com - Defense World
Investor Network: Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
2.36%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):